Update in serotonin and bone

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 9, 2010, Pages 4124-4132

  Bliziotes, Michael ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; FLUOXETINE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LP 533401; OXYGENASE INHIBITOR; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN HYDROXYLASE; TRYPTOPHAN HYDROXYLASE 2; UNCLASSIFIED DRUG; VITAMIN D; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LRP5 PROTEIN, HUMAN;

BONE; BONE DENSITY; BONE MASS; BONE METABOLISM; BRAIN; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; ENTEROCHROMAFFIN CELL; FEEDBACK SYSTEM; FRACTURE; HIP FRACTURE; HUMAN; INTESTINE; MEDLINE; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SCREENING; SEROTONIN BLOOD LEVEL; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKELETON; SPINE FRACTURE; TRABECULAR BONE; ANIMAL; BIOLOGICAL MODEL; CENTRAL NERVOUS SYSTEM; DRUG EFFECTS; METABOLISM; PHYSIOLOGY;

ANIMALS; BONE AND BONES; CENTRAL NERVOUS SYSTEM; HUMANS; INTESTINES; LDL-RECEPTOR RELATED PROTEINS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-5; MODELS, BIOLOGICAL; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 77956598675     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-0861     Document Type: Review

References (74)

1. Bliziotes MM, Eshleman AJ, Zhang XW, Wiren KM 2001 Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone 29:477-486
2. Westbroek I, van der Plas A, de Rooij KE, Klein-Nulend J, Nijweide PJ 2001 Expression of serotonin receptors in bone. J Biol Chem 276:28961-28968
3. Rapport MM, Green AA, Page IH 1948 Serum vasoconstrictor (serotonin). IV. Isolation and characterization. J Biol Chem 176:1243-1251
4. Rosen CJ 2009 Serotonin rising-the bone, brain, bowel connection. N Engl J Med 360:957-959
5. Rosen CJ 2009 Breaking into bone biology: serotonin's secrets. Nat Med 15:145-146
6. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schütz G, Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R, Ducy P, Karsenty G 2008 Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135:825-837
7. Walther DJ, Peter JU, Bashammakh S, Hörtnagl H, Voits M, Fink H, Bader M 2003 Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 299:76
8. aan het Rot M, Mathew SJ, Charney DS 2009 Neurobiological mechanisms in major depressive disorder. CMAJ 180:305-313
9. Arroll B, Macgillivray S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I 2005 Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med 3:449-456
10. Gershon MD, Tack J 2007 The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 132:397-414
11. Wade PR, Chen J, Jaffe B, Kassem IS, Blakely RD, Gershon MD 1996 Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. J Neurosci 16:2352-2364
12. Ni W, Watts SW 2006 5-Hydroxytryptamine in the cardiovascular system: focus on the serotonin transporter (SERT). Clin Exp Pharmacol Physiol 33:575-583
13. Warden SJ, Bliziotes MM, Wiren KM, Eshleman AJ, Turner CH 2005 Neural regulation of bone and the skeletal effects of serotonin (5-hydroxytryptamine). Mol Cell Endocrinol 242:1-9
14. Battaglino R, Fu J, Späte U, Ersoy U, Joe M, Sedaghat L, Stashenko P 2004 Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res 19:1420-1431
15. Bliziotes M, Eshleman A, Burt-Pichat B, Zhang XW, Hashimoto J, Wiren K, Chenu C 2006 Serotonin transporter and receptor expression in osteocytic MLO-Y4 cells. Bone 39:1313-1321
16. Gustafsson BI, Thommesen L, Stunes AK, Tommeras K, Westbroek I, Waldum HL, Slørdahl K, Tamburstuen MV, Reseland JE, Syversen U 2006 Serotonin and fluoxetine modulate bone cell function in vitro. J Cell Biochem 98:139-151
17. Locker M, Bitard J, Collet C, Poliard A, Mutel V, Launay JM, Kellermann O 2006 Stepwise control of osteogenic differentiation by 5-HT2B receptor signaling: nitric oxide production and phospholipase A2 activation. Cell Signal 18:628-639
18. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP 2002 High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346:1513-1521
19. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, DePaepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Jüppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML 2001 LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513-523
20. Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT, Recker SM, Van Eerdewegh P, Recker RR, Johnson ML 2002 A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high bone-mass trait. Am J Hum Genet 70:11-19
21. Baron R, Rawadi G 2007 Targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148:2635-2643
22. Glantschnig H, Hampton R, Wei N, Scott K, Nantermet P, Zhao J, Chen F, Fisher J, Su Q, Pennypacker B, Cusick T, Sandhu P, Reszka A, Strohl W, Flores O, Wang F, Kimmel D, An Z 2008 Fully human anti-DKK1 antibodies increase bone formation and resolve osteopenia in mouse models of estrogen-deficiency induced bone loss. J Bone Miner Res 23(Suppl 1):S60-S61
23. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C 2009 Sclerostin antibody treatment increases bone formation, bone mass and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24:578-588
24. Rothman RB, Zolkowska D, Baumann MH 2008 Serotonin (5-HT) transporter ligands affect plasma 5-HT in rats. Ann NY Acad Sci 1139:268-284
25. Liu Q, Yang Q, Sun W, Vogel P, Heydorn W, Yu XQ, Hu Z, Yu W, Jonas B, Pineda R, Calderon-Gay V, Germann M, O'Neill E, Brommage R, Cullinan E, Platt K, Wilson A, Powell D, Sands A, Zambrowicz B, Shi ZC 2008 Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract. J Pharmacol Exp Ther 325:47-55
26. Babij P, Zhao W, Small C, Kharode Y, Yaworsky PJ, Bouxsein ML, Reddy PS, Bodine PV, Robinson JA, Bhat B, Marzolf J, Moran RA, Bex F 2003 High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 18:960-974
27. Sawakami K, Robling AG, Ai M, Pitner ND, Liu D, Warden SJ, Li J, Maye P, Rowe DW, Duncan RL, Warman ML, Turner CH 2006 The Wnt coreceptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem 281:23698-23711
28. Yadav VK, Oury F, Suda N, Liu ZW, Gao XB, Confavreux C, Klemenhagen KC, Tanaka KF, Gingrich JA, Guo XE, Tecott LH, Mann JJ, Hen R, Horvath TL, Karsenty G 2009 A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 138:976-989
29. Yadav VK, Balaji S, Suresh PS, Liu XS, Lu X, Li Z, Guo XE, Mann JJ, Balapure AK, Gershon MD, Medhamurthy R, Vidal M, Karsenty G, Ducy P 2010 Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med 16:308-312
30. Warden SJ, Nelson IR, Fuchs RK, Bliziotes MM, Turner CH 2008 Serotonin (5-hydroxytryptamine) transporter inhibition causes bone loss in adult mice independently of estrogen deficiency. Menopause 15:1176-1183
31. Warden SJ, Robling AG, Sanders MS, Bliziotes MM, Turner CH 2005 Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 146:685-693
32. Westbroek I, Waarsing JH, van Leeuwen JP, Waldum H, Reseland JE, Weinans H, Syversen U, Gustafsson BI 2007 Long-term fluoxetine administration does not result in major changes in bone architecture and strength in growing rats. J Cell Biochem 101:360-368
33. Warden SJ, Hassett SM, Bond JL, Rydberg J, Grogg JD, Hilles EL, Bogenschutz ED, Smith HD, Fuchs RK, Bliziotes MM, Turner CH 2010 Psychotropic drugs have contrasting skeletal effects that are independent of their effects on physical activity levels. Bone 46:985-992
34. Bonnet N, Bernard P, Beaupied H, Bizot JC, Trovero F, Courteix D, Benhamou CL 2007 Various effects of antidepressant drugs on bone microarchitecture, mechanical properties and bone remodeling. Toxicol Appl Pharmacol 221:111-118
35. Zolkowska D, Baumann MH, Rothman RB 2008 Chronic fenfluramine administration increases plasma serotonin (5-hydroxytryptamine) to nontoxic levels. J Pharmacol Exp Ther 324:791-797
36. Mödder UI, Achenbach SJ, Amin S, Riggs BL, Melton 3rd LJ, Khosla S 2010 Relation of serum serotonin levels to bone density and structural parameters in women. J Bone Miner Res 25:415-422
37. Haney EM, Parimi N, Diem SJ, Ensrud K, Cauley JA, Orwoll ES, Bliziotes MM 2007 SSRI use is associated with increased risk of fracture among older men. J Bone Miner Res 22 (Suppl 1):S45
38. Richards JB, Papaioannou A, Adachi JD, Joseph L, Whitson HE, Prior JC, Goltzman D, CMOSRSG 2007 The impact of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 167:188-194
39. Diem SJ, Blackwell TL, Stone KL, Yaffe K, Haney EM, Bliziotes MM, Ensrud KE 2007 Use of antidepressants and rates of hip bone loss in older women: the Study of Osteoporotic Fractures. Arch Intern Med 167:1240-1245
40. Williams LJ, Henry MJ, Berk M, Dodd S, Jacka FN, Kotowicz MA, Nicholson GC, Pasco JA 2008 Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int Clin Psychopharmacol 23:84-87
41. Kinjo M, Setoguchi S, Schneeweiss S, Solomon DH 2005 Bone mineral density in subjects using central nervous system-active medications. Am J Med 118:1414
42. Spangler L, Scholes D, Brunner RL, Robbins J, Reed SD, Newton KM, Melville JL, Lacroix AZ 2008 Depressive symptoms, bone loss, and fractures in postmenopausal women. J Gen Intern Med 23:567-574
43. Vestergaard P, Rejnmark L, Mosekilde L 2006 Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int 17:807-816
44. Bolton JM, Metge C, Lix L, Prior H, Sareen J, Leslie WD 2008 Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol 28:384-391
45. Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton 3rd LJ 1987 Psychotropic drug use and the risk of hip fracture. N Engl J Med 316:363-369
46. Liu B, Anderson G, Mittmann N, To T, Axcell T, Shear N 1998 Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 351:1303-1307
47. Haney EM, Chan BK, Diem SJ, Ensrud KE, Cauley JA, Barrett-Connor E, Orwoll E, Bliziotes MM 2007 Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 167:1246-1251
48. Lewis CE, Ewing SK, Taylor BC, Shikany JM, Fink HA, Ensrud KE, Barrett-Connor E, Cummings SR, Orwoll E 2007 Predictors of non-spine fracture in elderly men: the MrOS Study. J Bone Miner Res 22:211-219
49. Ziere G, Dieleman JP, van der Cammen TJ, Hofman A, Pols HA, Stricker BH 2008 Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol 28:411-417
50. Hubbard R, Farrington P, Smith C, Smeeth L, Tattersfield A 2003 Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol 158:77-84
51. Psaty BM, Koepsell TD, Lin D, Weiss NS, Siscovick DS, Rosendaal FR, Pahor M, Furberg CD 1999 Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc 47:749-754
52. Coelho R, Silva C, Maia A, Prata J, Barros H 1999 Bone mineral density and depression: a community study in women. J Psychosom Res 46:29-35
53. Eskandari F, Martinez PE, Torvik S, Phillips TM, Sternberg EM, Mistry S, Ronsaville D, Wesley R, Toomey C, Sebring NG, Reynolds JC, Blackman MR, Calis KA, Gold PW, Cizza G 2007 Low bone mass in premenopausal women with depression. Arch Intern Med 167:2329-2336
54. Jacka FN, Pasco JA, Henry MJ, Kotowicz MA, Dodd S, Nicholson GC, Berk M 2005 Depression and bone mineral density in a community sample of perimenopausal women: Geelong Osteoporosis Study. Menopause 12:88-91
55. Mussolino ME, Jonas BS, Looker AC 2004 Depression and bone mineral density in young adults: results from NHANES III. Psychosom Med 66:533-537
56. Robbins J, Hirsch C, Whitmer R, Cauley J, Harris T 2001 The association of bone mineral density and depression in an older population. J Am Geriatr Soc 49:732-736
57. Silverman SL, Shen W, Minshall ME, Xie S, Moses KH 2007 Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. J Rheumatol 34:140-144
58. Wong SY, Lau EM, Lynn H, Leung PC, Woo J, Cummings SR, Orwoll E 2005 Depression and bone mineral density: is there a relationship in elderly Asian men? Results from MrOs (Hong Kong). Osteoporos Int 16:610-615 (Pubitemid 40897457)
59. Reginster JY, Deroisy R, Paul I, Hansenne M, Ansseau M 1999 Depressive vulnerability is not an independent risk factor for osteoporosis in postmenopausal women. Maturitas 33:133-137
60. Søgaard AJ, Joakimsen RM, Tverdal A, Fønnebø V, Magnus JH, Berntsen GK 2005 Long-term mental distress, bone mineral density and non-vertebral fractures. The Tromso Study. Osteoporos Int 16:887-897
61. Whitson HE, Sanders L, Pieper CF, Gold DT, Papaioannou A, Richards JB, Adachi JD, Lyles KW 2008 Depressive symptomatology and fracture risk in community-dwelling older men and women. Aging Clin Exp Res 20:585-592
62. Whooley MA 1999 Depression and medical illness. Ann Epidemiol 9:281-282
63. Whooley MA, Cauley JA, Zmuda JM, Haney EM, Glynn NW 2004 Depressive symptoms and bone mineral density in older men. J Geriatr Psychiatry Neurol 17:88-92
64. Ensrud KE, Blackwell TL, Mangione CM, Bowman PJ, Whooley MA, Bauer DC, Schwartz AV, Hanlon JT, Nevitt MC 2002 Central nervous system-active medications and risk for falls in older women. J Am Geriatr Soc 50:1629-1637
65. Kerse N, Flicker L, Pfaff JJ, Draper B, Lautenschlager NT, Sim M, Snowdon J, Almeida OP 2008 Falls, depression, and antidepressants in later life: a large primary care appraisal. PLoS ONE 3:e2423
66. Thapa PB, Gideon P, Cost TW, Milam AB, Ray WA 1998 Antidepressants and the risk of falls among nursing home residents. N Engl J Med 339:875-882
67. Ensrud KE, Blackwell T, Mangione CM, Bowman PJ, Bauer DC, Schwartz A, Hanlon JT, Nevitt MC, Whooley MA 2003 Central nervous system active medications and risk for fractures in older women. Arch Intern Med 163:949-957
68. Forsén L, Meyer HE, Søgaard AJ, Naess S, Schei B, Edna TH 1999 Mental distress and risk of hip fracture. Do broken hearts lead to broken bones? J Epidemiol Community Health 53:343-347
69. Tolea MI, Black SA, Carter-Pokras OD, Kling MA 2007 Depressive symptoms as a risk factor for osteoporosis and fractures in older Mexican American women. Osteoporos Int 18:315-322
70. French DD, Campbell R, Spehar A, Cunningham F, Bulat T, Luther SL 2006 Drugs and falls in community-dwelling older people: a national veterans study. Clin Ther 28:619-630
71. Hartikainen S, Lönnroos E, Louhivuori K 2007 Medication as a risk factor for falls: critical systematic review. J Gerontol A Biol Sci Med Sci 62:1172-1181
72. Sterke CS, Verhagen AP, van Beeck EF, van der Cammen TJM 2008 The influence of drug use on fall incidents among nursing home residents: a systematic review. Int Psychogeriatr 20:890-910
73. Warden SJ, Robling AG, Haney EM, Turner CH, Bliziotes MM 2010 The emerging role of serotonin (5-hydroxytryptamine) in the skeleton and its mediation of the skeletal effects of low-density lipoprotein receptor-related protein 5 (LRP5). Bone 46:4-12
74. Haney EM, Warden SJ, Bliziotes MM 2010 Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management? Bone 46:13-17